BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

284 related articles for article (PubMed ID: 24953177)

  • 1. A small-molecule inhibitor of PIM kinases as a potential treatment for urothelial carcinomas.
    Foulks JM; Carpenter KJ; Luo B; Xu Y; Senina A; Nix R; Chan A; Clifford A; Wilkes M; Vollmer D; Brenning B; Merx S; Lai S; McCullar MV; Ho KK; Albertson DJ; Call LT; Bearss JJ; Tripp S; Liu T; Stephens BJ; Mollard A; Warner SL; Bearss DJ; Kanner SB
    Neoplasia; 2014 May; 16(5):403-12. PubMed ID: 24953177
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Transcription and translation are primary targets of Pim kinase inhibitor SGI-1776 in mantle cell lymphoma.
    Yang Q; Chen LS; Neelapu SS; Miranda RN; Medeiros LJ; Gandhi V
    Blood; 2012 Oct; 120(17):3491-500. PubMed ID: 22955922
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The Pim kinases: new targets for drug development.
    Swords R; Kelly K; Carew J; Nawrocki S; Mahalingam D; Sarantopoulos J; Bearss D; Giles F
    Curr Drug Targets; 2011 Dec; 12(14):2059-66. PubMed ID: 21777193
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Anti-tumour effects of PIM kinase inhibition on progression and chemoresistance of hepatocellular carcinoma.
    Leung MS; Chan KK; Dai WJ; Wong CY; Au KY; Wong PY; Wong CC; Lee TK; Ng IO; Kao WJ; Lo RC
    J Pathol; 2020 Sep; 252(1):65-76. PubMed ID: 32558942
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Targeting PIM kinase enhances the activity of sunitinib in renal cell carcinoma.
    Mahalingam D; Espitia CM; Medina EC; Esquivel JA; Kelly KR; Bearss D; Choy G; Taverna P; Carew JS; Giles FJ; Nawrocki ST
    Br J Cancer; 2011 Nov; 105(10):1563-73. PubMed ID: 22015557
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Biochemical changes of salivary gland adenoid cystic carcinoma cells induced by SGI-1776.
    Hou X; Yu Y; Feng J; Wang J; Zheng C; Ling Z; Ge M; Zhu X
    Exp Cell Res; 2017 Mar; 352(2):403-411. PubMed ID: 28228352
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Mechanisms of cytotoxicity to Pim kinase inhibitor, SGI-1776, in acute myeloid leukemia.
    Chen LS; Redkar S; Taverna P; Cortes JE; Gandhi V
    Blood; 2011 Jul; 118(3):693-702. PubMed ID: 21628411
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The novel anti-adipogenic effect and mechanisms of action of SGI-1776, a Pim-specific inhibitor, in 3T3-L1 adipocytes.
    Park YK; Hong VS; Lee TY; Lee J; Choi JS; Park DS; Park GY; Jang BC
    Int J Mol Med; 2016 Jan; 37(1):157-64. PubMed ID: 26719859
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Biological effects of the Pim kinase inhibitor, SGI-1776, in multiple myeloma.
    Cervantes-Gomez F; Chen LS; Orlowski RZ; Gandhi V
    Clin Lymphoma Myeloma Leuk; 2013 Sep; 13 Suppl 2(0 2):S317-29. PubMed ID: 23988451
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Pim kinase inhibitor, SGI-1776, induces apoptosis in chronic lymphocytic leukemia cells.
    Chen LS; Redkar S; Bearss D; Wierda WG; Gandhi V
    Blood; 2009 Nov; 114(19):4150-7. PubMed ID: 19734450
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The Pim kinase inhibitor SGI-1776 decreases cell surface expression of P-glycoprotein (ABCB1) and breast cancer resistance protein (ABCG2) and drug transport by Pim-1-dependent and -independent mechanisms.
    Natarajan K; Bhullar J; Shukla S; Burcu M; Chen ZS; Ambudkar SV; Baer MR
    Biochem Pharmacol; 2013 Feb; 85(4):514-24. PubMed ID: 23261525
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Preclinical characterization of INCB053914, a novel pan-PIM kinase inhibitor, alone and in combination with anticancer agents, in models of hematologic malignancies.
    Koblish H; Li YL; Shin N; Hall L; Wang Q; Wang K; Covington M; Marando C; Bowman K; Boer J; Burke K; Wynn R; Margulis A; Reuther GW; Lambert QT; Dostalik Roman V; Zhang K; Feng H; Xue CB; Diamond S; Hollis G; Yeleswaram S; Yao W; Huber R; Vaddi K; Scherle P
    PLoS One; 2018; 13(6):e0199108. PubMed ID: 29927999
    [TBL] [Abstract][Full Text] [Related]  

  • 13. PIM kinases as therapeutic targets against advanced melanoma.
    Shannan B; Watters A; Chen Q; Mollin S; Dörr M; Meggers E; Xu X; Gimotty PA; Perego M; Li L; Benci J; Krepler C; Brafford P; Zhang J; Wei Z; Zhang G; Liu Q; Yin X; Nathanson KL; Herlyn M; Vultur A
    Oncotarget; 2016 Aug; 7(34):54897-54912. PubMed ID: 27448973
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Functional role and therapeutic potential of the pim-1 kinase in colon carcinoma.
    Weirauch U; Beckmann N; Thomas M; Grünweller A; Huber K; Bracher F; Hartmann RK; Aigner A
    Neoplasia; 2013 Jul; 15(7):783-94. PubMed ID: 23814490
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Cell-permeable carboxyl-terminal p27(Kip1) peptide exhibits anti-tumor activity by inhibiting Pim-1 kinase.
    Morishita D; Takami M; Yoshikawa S; Katayama R; Sato S; Kukimoto-Niino M; Umehara T; Shirouzu M; Sekimizu K; Yokoyama S; Fujita N
    J Biol Chem; 2011 Jan; 286(4):2681-8. PubMed ID: 21062737
    [TBL] [Abstract][Full Text] [Related]  

  • 16. 2-Thioxothiazolidin-4-one Analogs as Pan-PIM Kinase Inhibitors.
    Yun Y; Hong VS; Jeong S; Choo H; Kim S; Lee J
    Chem Pharm Bull (Tokyo); 2021; 69(9):854-861. PubMed ID: 34470949
    [TBL] [Abstract][Full Text] [Related]  

  • 17. RNA-Seq analysis reveals that spring viraemia of carp virus induces a broad spectrum of PIM kinases in zebrafish kidney that promote viral entry.
    Pereiro P; Álvarez-Rodríguez M; Valenzuela-Muñoz V; Gallardo-Escárate C; Figueras A; Novoa B
    Fish Shellfish Immunol; 2020 Apr; 99():86-98. PubMed ID: 32004617
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Pharmacologic inhibition of Pim kinases alters prostate cancer cell growth and resensitizes chemoresistant cells to taxanes.
    Mumenthaler SM; Ng PY; Hodge A; Bearss D; Berk G; Kanekal S; Redkar S; Taverna P; Agus DB; Jain A
    Mol Cancer Ther; 2009 Oct; 8(10):2882-93. PubMed ID: 19825806
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Targeting of glioblastoma cell lines and glioma stem cells by combined PIM kinase and PI3K-p110α inhibition.
    Iqbal A; Eckerdt F; Bell J; Nakano I; Giles FJ; Cheng SY; Lulla RR; Goldman S; Platanias LC
    Oncotarget; 2016 May; 7(22):33192-201. PubMed ID: 27120806
    [TBL] [Abstract][Full Text] [Related]  

  • 20. PIM Kinase Inhibitors Kill Hypoxic Tumor Cells by Reducing Nrf2 Signaling and Increasing Reactive Oxygen Species.
    Warfel NA; Sainz AG; Song JH; Kraft AS
    Mol Cancer Ther; 2016 Jul; 15(7):1637-47. PubMed ID: 27196781
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.